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A cross-over medication trial for patients with autosomal dominant
hypertension with brachydactyly. We examined a family with autosomal-
dominant hypertension and brachydactyly from northeastern Turkey. The
hypertension was defined as severe, resulting in stroke before age 50 years,
featuring normal renin, aldosterone, and catecholamine responses, and
did not appear to be salt-sensitive. The responsible gene resides on
chromosome 12p. To determine which medications were most effective,
we performed a prospective clinical trial. We studied 13 affected individ-
uals in a randomized double-blind, cross-over trial including a beta-
blocker (BBL), alpha-blocker (ABL), calcium channel blocker (CCB),
converting enzyme inhibitor (CEI), and hydrochlorothiazide (HCT) and
placebo (PLA). We then added moxonidine (MOX) and continued the
trial for an additional period in a single-blind fashion. Each drug was given
for four weeks with an option to double the dose after two weeks; each
washout period comprised two weeks. Blood, 24-hour urine, and saliva
were studied at the outset, and blood and urine samples were obtained at
the end of each phase. Blood pressure (BP) and heart rate measurements
were with the patient ambulatory at 24 hours. All regimens required
doubled doses at two weeks. Beta blocker, CCB, CEI, and ABL lowered
BP (6 to 10 mm Hg) and BP load compared to PLA, while HCT and MOX
did not. Converting enzyme inhibitor and HCT increased plasma renin
activity (PRA), while BBL lowered PRA. The 24-hour urine analysis
indicated a high dietary salt intake with a low potassium and calcium
intake. The salivary electrolytes showed similar sodium and potassium
concentrations, while chloride values were significantly higher in affected
than nonaffected subjects. Thus, this monogenic form of hypertension
resembles nonsalt-sensitive essential hypertension in that BBL, CCB, CEI,
and ABL were effective, while HCT was not. The BP reduction was similar
to other single drug trials in essential hypertension. The high salivary
chloride values suggest an additional intermediary phenotype that may be
related to electrolyte transport. These results raise the possibility that an
as yet unknown hypertensive mechanism is operative in these subjects.
Much has been learned about the pathogenesis of hypertension
from unusual forms of monogenic hypertension such as glucocor-
ticoid remediable aldosteronism [1], Liddle syndrome [2], and the
syndrome of apparent mineralocorticoid excess [3]. In these
diseases, the response to antihypertensive therapy was a major
clue to which genes might be responsible for the individual
syndromes [4]. We examined a large kindred from northeastern
Turkey with a monogenic form of autosomal-dominant hyperten-
sion, which cosegregates with brachydactyly. Affected persons
generally die of stroke before age 50 years [5]. We mapped the
responsible gene(s) to chromosome 12p [6]. In an earlier clinical
study, we found that the hypertension is elicited by a marked
increase in peripheral vascular resistance, that the renin, aldoste-
rone, and catecholamine values respond normally to volume
expansion and contraction, and that affected individuals do not
appear to be salt-sensitive [7]. With few exceptions, none of the
affected family members were being treated for hypertension. We
conducted a randomized, cross-over, placebo-controlled, double-
blind trial of five medications, to determine the most effective
pharmacological treatment. Since only a single gene, and thereby
a single mechanism, is responsible for hypertension in this kin-
dred, we reasoned that a single drug might be more effective in all
subjects than all other drugs combined. A pharmacological phe-
notype might shed light on pathogenic mechanisms. We based our
drug selection on medications recommended by the World Health
Organization/International Society of Hypertension for the first-
line treatment of hypertension, namely thiazide diuretics (HCT),
beta blockers (BBL), alpha blockers (ABL), angiotensin convert-
ing enzyme inhibitors (CEI), and calcium channel blockers (CCB)
[8]. Towards the end of the study, the imidazoline receptor agonist
moxonidine (MOX) was made available to us, so we also tested
that drug in the last phase of the study, albeit in a single-blinded
fashion. The drugs were tested against a run-in phase, as well as
against placebo (PLA). Twenty-four-hour ambulatory blood pres-
sure measurements were made at the end of each phase, as well as
24-hour urine collections for electrolyte excretion and blood
samples for serum chemistries. To our knowledge, this trial is the
first randomized double-blind, placebo-controlled cross-over
study of “first line” antihypertensive medications.
METHODS
We recruited 17 family members with hypertension and brachy-
dactyly. The protocol was approved of the internal review boards
of both the Hacettepe University, Ankara, Turkey, and the
Humboldt University of Berlin, Germany. Informed written con-
sent in the Turkish language was obtained from all participants.
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The inclusion criteria were affected status (brachydactyly), blood
pressure . 140/90 mm Hg for subjects $ 16 years and . 95
percentile for age (. 136/. 86 mm Hg) for subjects , 16 years of
age [9]. Three subjects were , 16 years old: a 13-year-old girl, a
15-year-old boy and a 15-year-old girl. Exclusion criteria were
secondary hypertensive complications (stroke, heart disease, renal
disease), pregnancy, or plans to become pregnant and lactation.
We elected to study several younger individuals if they were
hypertensive and were willing and able to participate. We did so
knowing the prognosis of the disease and also because we had
decided to treat all subjects . 35 years routinely to prevent stroke.
The 5 men and 12 women, none of whom had ever received
antihypertensive treatment, ranged in age from 13 to 34 years. A
Turkish physician and Turkish speaking medical student moved to
the home village of the subjects and lived there for 12 months
during the course of the study. They performed all the examina-
tions, obtained the blood and urine samples, and were available to
the subjects for any problems, whether or not they were related to
the study.
A pill count was conducted every two weeks of the study.
Compliance was defined as no more than a two tablet error in
terms of pill count. Furthermore, at that time the subjects were
questioned extensively regarding their general health, their energy
levels and the presence of fatigue, any changes in their psycho-
logical well being, their general level of function, and satisfaction
with their physical abilities. The answers were monitored and
comparisons of the various phases were made at the end of the
study.
After the initial subject selection, the subjects were observed for
one month without active medication, but with placebo tablets
identical to those described below. Then they underwent 24-hour
ambulatory blood pressure and heart rate monitoring (Space Labs
90217-2; Space Labs Inc., Redmond, WA, USA). Measurements
were taken every 15 minutes during the day and half-hourly at
night. We accepted 24 hour measurements with less than 20%
missing values, although for the majority of subjects we encoun-
tered less than 10% missing values. Day was defined as 0600 to
2200 hours, while night was defined as 2200 to 0600 hours. This
time interval corresponded well with the subjects’ work and
sleeping habits. The subjects were also instructed in the collection
of a 24-hour urine specimen for sodium, potassium, calcium, and
creatinine excretion analysis. On the following morning, the
subjects were weighed and measured and their blood was ob-
tained for electrolytes, plasma renin activity (PRA), and plasma
aldosterone (ALD) values. Electrolytes and creatinine in blood
and urine were measured by automated techniques. Plasma renin
activity and ALD were measured by radioimmunoassay. In addi-
tion to the above examinations, we also collected saliva from the
17 subjects, as well as from 10 nonaffected relatives. The saliva
was gathered between meals in the morning; some subjects
chewed on rubber bands to assist in stimulating saliva. Sodium,
potassium and chloride were measured in the saliva in order to
determine any additional phenotypic characteristics of the sub-
jects that might have to do with electrolyte transport [10].
Thereafter, the subjects were randomized to one of six regi-
mens (PLA, HCT, BBL, ABL, CEI, or CCB) for a two week
period, at the end of which they were examined by the physicians.
If their blood pressures were above the study entry criteria, the
subjects were moved to a higher dose of that regimen. At the end
of another two weeks, the 24-hour ambulatory blood pressure and
heart rate measurements, the urine collections, and the blood
specimens were repeated. A two-week washout period was begun,
at the end of which another of the six regimens was initiated.
During the washout period, the subjects were rotated to PLA
medication. Thus, they ingested the same appearing capsule and
tablet after the run-in period for the entire duration of the study.
At two-weekly intervals, the subjects were questioned in detail
about possible side effects. Towards the end of the study, we
decided to include a trial of MOX therapy. Since that regimen
could no longer be randomized into the study, we gave MOX after
the last regimen in the same fashion and in the same capsule and
tablet combination, as all the other regimens. All subjects re-
ported in this study participated in all seven regimens, including
MOX. We gave the following medications and doses: hydrochlo-
rothiazide 25 mg/day, metoprolol (zero order kinetic single daily
dose formulation) 50 or 100 mg/day, doxasosin 2 or 4 mg/day,
ramipril 2.5 or 5 mg/day, felodipine 5 or 10 mg/day, and mox-
onidine 0.2 or 0.4 mg/day.
To more precisely estimate the stress which the cardiovascular
tree experienced during each blood pressure-measurement day,
we calculated the blood pressure load. The blood pressure load
encompasses not only the blood pressure level above a certain
threshold, but also the time of exposure. The threshold has been
established as . 140/90 mm Hg for adults. The blood pressure
load has been shown to correlate with complications better than
casual blood pressure determinations [11]. Blood pressure load
was calculated as the mean area under the blood pressure curve
(AUC) for all values above a 140/90 mm Hg threshold for
subjects . 16 years. For subjects , 16 years of age, we calculated
the area under the blood pressure curve for all values . 136/86
mm Hg. The blood pressure load value is expressed as mm Hg
[11]. Twenty-four hour AUC was divided by time to form blood
pressure load as a measure of total vessel overload. We did not
distinguish the load in terms of diurnal and nocturnal values, since
we were interested in stress on the vasculature rather than in the
circadian variation per se. We also indicated the percent of all
blood pressure determinations during 24 hours, which were above
the threshold values.
Statistical analysis was conduced using SPSS (SPSS Inc., Chi-
cago, IL, USA). Effects of medications were tested using repeated
measures analysis of variance. Different medications were tested
against run-in and placebo by pair-wise t-tests with Bonferoni’s
correction. To examine differences in response to the various
medications, the medication effect order was tested by Friedman’s
rank test. The test allows the gerenal determination of differences
in effect, although differences between specific treatments cannot
be discerned. The data are presented as mean 6 SD. A P value
,0.05 was considered statistically significant.
RESULTS
Twelve subjects completed the trial. One 28-year-old woman
developed marked dizziness and light headedness during the first
phase of the treatment and requested that the therapy be stopped.
She agreed to continue in the study for the next and subsequent
phases and did so successfully, although we did not include her
data in the analysis. When we unblinded her treatment, we
learned that she had ingested PLA during her episodes of light
headedness. Three other young women left the study after they
announced plans to marry and had altered their pregnancy plans.
Another man was not able to participate in the MOX segment of
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the study. His data were also not included in the analysis. The pill
counts showed that the subjects’ compliance was excellent. All
regimens met our criteria for compliance. Generally, there were
no errors. The standardized questionnaires to establish possible
side effects were evaluated and no differences among the regi-
mens could be identified. We excluded all data on subjects failing
to complete all arms of the study so that we could employ a
repeated measures analysis of variance approach. However, by so
doing, we reduced our numbers of subjects accordingly. The
subjects ranged in age from 13 to 34 years. Five were men and
eight were women. The body mass index ranged from 20.3 to 26.8.
Table 1 shows the 24-hour blood pressure and heart rate data
for the run-in phase and seven treatments. The dose of the drugs
required doubling at two weeks in every instance. Thus, the higher
dose was tested at four weeks. Systolic and diastolic blood
pressure, heart rate, daytime and night time blood pressures and
heart rates, as well as the systolic and diastolic blood pressure
loads all showed a significant effect of treatment. The day/night
blood pressure difference (dipping phenomenon) was not influ-
enced by treatment. All subjects exhibited an appropriate diurnal
blood pressure variation. We were able to assign rank order scores
to the treatments compared to PLA. For systolic blood pressure
these were: BBL, CCB, CEI, ABL, HCT, MOX, and PLA. The
rank order for diastolic blood pressure was little different. The
BBL treatment had a significant effect on heart rate.
Figure 1 shows the daytime values from 24-hour blood pressure
and heart rate measurements in the same rank order as given in
Table 1. Significant differences between drug regimens and
run-in, as well as significant differences with placebo, are indi-
cated. Beta blockers, CCB, CEI, and ABL lowered blood pressure
compared to PLA, while HCT and MOX did not. Figure 2 shows
the 24-hour blood pressure load. The blood pressure load was
significantly reduced for the same regimens, compared to PLA.
We also sought to find effects of age and could identify none.
Table 2 shows the electrolyte values in blood and urine, as well
as PRA and ALD determinations. Plasma electrolytes, including
calcium and phosphate, were not influenced by any of the
regimens. Plasma renin activity and ALD increased significantly
with HCT treatment compared to the other regimens; PRA
increased significantly with CEI treatment, while ALD did not.
Renin values with the BBL treatment were significantly lower
than with the PLA treatment. The 24-hour urine collections
showed considerable variability, probably indicating compliance
difficulties. The 24-hour sodium and potassium excretion rates
were constant under the regimens as would be predicted by steady
state. The 24-hour calcium excretion was variable, and although
the values decreased numerically with HCT compared to run-in,
significance could not be shown. The salivary sodium values in
nonaffected persons were 10.4 6 3.2 compared to 14.5 6 9.4
mmol/liter in affected subjects; the corresponding potassium
values were 21.4 6 5.5 versus 24.3 6 5.6 mmol/liter, respectively.
On the other hand, the corresponding chloride values were 16.9 6
5.0 versus 24.8 6 7.6 mmol/liter, respectively (P , 0.05). A
comparison between anions and cations (anion gap) between the
two groups ([Na1K]-Cl) revealed values of 14.9 6 4.8 versus
14.1 6 6.3 mmol/liter, respectively, which were not significantly
different.
DISCUSSION
The important findings in this study were that BBL, CCB, CEI
and ABL lowered blood pressure in these subjects with mono-
genic hypertension and brachydactyly, while HCT and MOX did
not. These findings are consistent with the suggestion that this
form of monogenic hypertension resembles salt-resistent essential
hypertension. To our knowledge, this is the first double-blind,
cross-over study involving the agents suggested as first-line drugs
for the treatment of essential hypertension. Clearly, it is the first
such study employing 24-hour blood pressure monitoring. Al-
though our study was relatively brief, the blood pressure reduc-
tions we observed with BBL, CCB, CEI, and ABL were similar in
magnitude than those reported in the Treatment of Mild Hyper-
tension (TOMHS) Study [12]. That investigation had a parallel
Table 1. Blood pressure (mm Hg) and heart rate (beats/min) results obtained from 24-hour ambulatory measurements in the subjects (mean 6 SD)
Variable RUN BBL CCB CEI ABL HCT MOX PLA P
SYS 24 hr 148 6 18 135 6 18ab 137 6 13ab 138 6 15ab 140 6 16a 142 6 18a 144 6 15 145 6 16 0.01
DIA 24 hr 97 6 13 87 6 13ab 90 6 11ab 91 6 12ab 91 6 12a 94 6 15 94 6 13 95 6 13 0.01
HR 24 hr 74 6 5 65 6 6ab 77 6 7 75 6 7 77 6 8 76 6 4 73 6 5 75 6 5 0.01
SYS day 153 6 18 129 6 19ab 141 6 14ab 142 6 15ab 143 6 16a 146 6 19a 147 6 14 148 6 16 0.01
DIA day 101 6 13 90 6 14ab 93 6 11a 93 6 11ab 94 6 12a 97 6 15 97 6 12 98 6 13 0.01
HR day 77 6 6 67 6 7ab 81 6 8 78 6 8 81 6 9 79 6 6 76 6 6 78 6 5 0.01
SYS night 132 6 19 119 6 17ab 120 6 14ab 124 6 17a 125 6 18 123 6 15a 132 6 20 128 6 17 0.01
DIA night 84 6 14 74 6 13a 77 6 12a 80 6 14 80 6 15 79 6 14a 85 6 15 82 6 15 0.01
HR night 65 6 6 59 6 5ab 63 6 6 63 6 7 65 6 6 64 6 4 64 6 5 65 6 5 0.05
SYS load mm Hg 13 6 12 6 6 9ab 6 6 6ab 7 6 8ab 8 6 8a 9 6 10 10 6 11 10 6 10 0.01
DIA load mm Hg 11 6 8 5 6 6ab 5 6 5a 6 6 6a 7 6 6a 9 6 9 9 6 8 9 6 8 0.01
SYS load % 64 6 30 40 6 31ab 45 6 27ab 47 6 30 50 6 33 51 6 33 56 6 25 60 6 29 0.01
DIA load % 70 6 25 46 6 31ab 54 6 25a 58 6 26a 58 6 30 63 6 28 63 6 27 65 6 26 0.01
SYS day/night 21 6 5 19 6 12 21 6 8 18 6 7 19 6 12 23 6 7 15 6 9 20 6 10 NS
DIA day/night 17 6 6 16 6 7 16 6 7 13 6 7 14 6 9 18 6 6 12 6 9 16 6 8 NS
SYS rank — 2.9 3.3 3.4 3.7 4.3 5.1 5.4 0.05
DIA rank — 2.3 3.3 3.7 3.6 4.8 4.8 5.4 0.05
HR rank — 1.1 4.7 3.9 4.8 5.1 3.8 4.6 0.05
Abbreviations are: RUN, run in; BBL, beta blocker; CCB, calcium channel blocker; CEI, converting enzyme inhibitor; ABL, alpha blocker; HCT,
hydrochlorothiazide; MOX, moxonidine; PLA, placebo. Blood pressure load is expressed as the area under the curve of all values above a given
threshold as mm Hg and the % of all values above the threshold as described in Methods.
a Significantly different from RUN
b Significantly different PLA
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design, the numbers of subjects were far greater, and the period of
observation extended to four years.
We had hoped to find a single treatment that would give us
insight into the mechanism of this hypertensive syndrome. In
glucocorticoid remediable aldosteronism, the response to low
dose of prednisone, response to thiazide diuretics, response to
spironolactone, and the appearance of abnormal steroid urinary
metabolites gave important clues as to what genetic mechanisms
were operative [13]. Liddle himself suggested, on the basis of his
patients’ response to antihypertensive treatment, what the nature
Liddle syndrome was likely to be [14]. The resemblance of
apparent mineralocorticoid excess to licorice gluttony, as well as
the response to thiazide diuretics and to spironolactone eluci-
dated the candidate gene that proved to be responsible [15]. On
the other hand, our results do not point to an obvious candidate
gene. However, we do not view our results as a “negative” study
any more than we would consider the TOMHS results to be a
negative study [11]. The fact that we found no straightforward
pharmacological phenotype suggests that this monogenic hyper-
tension may be of particular relevance to essential hypertension.
The cross-over design is powerful; however, the small number
of subjects in our study and the considerable variability in blood
pressure are limiting factors. The hypertension characterized by
these subjects greatly age-dependent. The fact that we included
three subjects , 16 years of age increased the blood pressure
variability. These persons were the least hypertensive and thereby
exhibited the mildest blood pressure reductions with treatment.
We did not feel justified in including persons . 35 years of age in
our study, because of the well documented risk of stroke in this
family. We treated such persons with two or three drug regimens,
generally with a BBL, CCB, CEI combination.
We conducted pill counts that suggested that our subjects were
compliant. Also facilitating compliance was our close relationship
with the family and their very clear awareness of the consequences
of their disease. Furthermore, we observed a decrease in PRA
with BBL therapy, an increase in PRA with CEI therapy, and an
increase in both PRA and ALD with HCT therapy. These
expected reactions support the notion that the medications were
being ingested and were effective.
Hydrochlorothiazide failed to significantly reduce blood pres-
sure in our subjects. One interpretation of this result is that
persons with autosomal-dominant hypertension with brachydac-
tyly are indeed not salt-sensitive. Our earlier phenotypization
study used an accepted protocol to determine salt-sensitivity and
resistance and give similar results [7]. An alternative view is that
the substantial salt intake of our subjects made the chances for
HCT therapy remote. The urinary sodium excretion of our
subjects ranged from 177 to 256 mmol/day. These amounts exceed
even the highest salt intakes observed in the 52 centers of the
Intersalt study [16]. However, the dose of HCT we administered
(25 mg/day) is the dose currently recommended and has been
used effectively in major intervention trials [17]. The fact that the
renin-agniotensin system was influenced by thiazide treatment
attests to volume effects produced by that drug.
The 24-hour urine collections of our subjects revealed not only
Fig. 1. Day-time values from 24-hour
ambulatory blood pressure measurements and
heart rate in the subjects at the end of each
regimen. Significant differences between
treatment and run-in (*P , 5% vs. RUN), and
treatment and placebo (1P , 5% vs. PLA), are
indicated.
Fig. 2. Twenty-four hour blood pressure load determined at the end of
each regimen. Symbols are: (f) systolic BP load; (u) diastolic BP load.
Significant differences between treatment and run-in (*P , 5% vs. RUN),
and treatment and placebo (1P , 5% vs. PLA), are indicated.
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a very generous salt intake, but also a surprisingly modest intake
of potassium and calcium. Both have been suggested to be
important to blood pressure regulation [18, 19]. Potassium intake
has been particularly related to the occurrence of stroke [20]. An
avenue for nonpharmacological intervention in terms of modify-
ing electrolyte intake may be possible in affected family members.
It was interesting to find an elevated salivary chloride in our
subjects compared to nonaffected family members. We do not
believe this finding to be artifactual, since the sodium and
potassium values were not different and since the electrolyte
relationships (salivary anion gap) were maintained. Skrabal et al
[10] found earlier that young salt-sensitive persons had lower
salivary sodium concentrations compared to salt-resistant individ-
uals. These findings prompted the present measurements. We
have no explanation for this interesting intermediary phenotype as
yet. The 6 cm segment on chromosome 12p currently receiving
our attention [21] does contain potential candidate genes for
channels. Genes related to the L-type calcium channel lie outside
of our segment. The gene for the adenosine 59-triphosphate
(ATP)-dependent potassium channel lies within our segment;
however, we sequenced the three exons of that gene and found no
mutations. The ATP-dependent potassium channels have impor-
tant effects on vascular tone [22]. Nevertheless, the smooth
muscle cell sufonyl urea receptor gene, which regulates the
ATP-dependent potassium channel, is very close in proximity and
remains a candidate [23]. Interestingly, the sulfonyl urea drug
glibenclamide exercises inhibitory effects on the cystic fibrosis
transmembrane regulator and can thereby influence chloride
channels [24]. We plan additional patch clamp studies on fibro-
blasts and lymphoblasts from our subjects to further elucidate this
possibility.
We were surprised that MOX was not more effective in
lowering blood pressure in our subjects. We had included MOX
because of our observation that affected individuals exhibit an
anomalous looping posterior inferior cerebellar artery, which
could be impinging on the ventrolateral medulla. We conducted
magnetic resonance imaging investigations in 15 affected and 11
nonaffected members of this family and found such anomalies in
all affected members, while no nonaffected persons had such
findings [25]. These anomalies, termed neurovascular compres-
sion, may elicit a neurogenic hypertension [26]. Neurovascular
compression may be readily identified with magnetic resonance
imaging and has been found to be more prevalent in patients with
essential hypertension than in those with secondary hypertension
[27]. The fact that MOX was not effective in these subjects by no
means rules out a possible central nervous system cause for the
hypertension; however, supportive evidence for this hypothesis
from MOX treatment or ABL therapy was not forthcoming in our
study. We have no specific reason to believe that the MOX
formulation we employed was deficient in terms of bioavailability.
However, since we did not monitor drug serum concentrations, we
cannot be certain that effective concentrations were achieved.
On the basis of our findings, we have begun treating our
subjects permanently. Most of our subjects are receiving a BBL
plus CEI or BBL plus CCB combination therapy. Women desiring
to become pregnant have been advised to take the BBL treatment.
We hope to be able to prevent stroke in our subjects with
antihypertensive therapy. Since we have reasonable actuarial
information on this family from prior generations, it is quite
conceivable that we will be able to assess the effect of our
treatment in the future. All affected family members are now
receiving antihypertensive therapy.
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APPENDIX
Abbreviations used in this article are: HCT, thiazide diuretics; BBL,
beta blockers; ABL, alpha blockers; CEI, angiotensin converting enzyme
inhibitors; CCB, calcium channel blockers; MOX, moxonidine; PLA,
placebo; AUC, area under the blood pressure curve; BP, blood pressure;
PRA, plasma renin activity; ALD, plasma aldosterone.
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